Onderzoeker

Sylvie Rottey

Disciplines:Kankertherapie, Oncologie niet elders geclassificeerd, Kankerbiologie

Publicaties

1 - 10 van 201

Potential clinical applications of current and future oral forms of desmopressin (review)(2024)
Auteurs: Karel Everaert, Tove Holm-Larsen, George Bou Kheir, Sylvie Rottey, Jeffrey Weiss, Johan Vande Walle, Abdo Kabarriti, Lien Dossche, François Hervé, Anne-Françoise Spinoit, et al.
Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants(2023)
Auteurs: Marian Iwamoto, Kelly E. Duncan, Prachi K. Wickremasingha, Tian Zhao, Maria V. Liberti, Lieselotte Lemoine, Tatjana Decaesteker, Sylvie Rottey, Brian M. Maas, Gillian Gillespie, et al.
Pagina's: 1947 - 1956
A randomized, double-blind, placebo-controlled, phase 1 trial of radiopaque islatravir-eluting subdermal implants for pre-exposure prophylaxis against HIV-1 infection(2023)
Auteurs: RP Matthews, X Zang, SE Barrett, A Koynov, A Goodey, T Heimbach, VL Weissler, C Leyssens, T Reynders, Z Xu, et al.
Pagina's: 310 - 316
Single ascending doses of REGN7999, a monoclonal antibody inhibitor of TMPRSS6, increase serum hepcidin and cause deep, sustained reductions in serum iron in healthy human volunteers(2023)
Volume: 142
Auteurs: Sylvie Rottey, Nikhil Singh, Emily Labriola-Tompkins, Heinrich E Lob, Kusha Mohammadi, Hazem Hassan, Lorna Farrelly, Swati Duggal, Harvey Chin, Sarah Hatsell, et al.
Pagina's: 3841 - 3841
Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate cancer(2023)
Auteurs: Jonathan Chou, Emily A. Egusa, Sinan Wang, Michelle L. Badura, Fei Lee, Anil P. Bidkar, Jun Zhu, Tanushree Shenoy, Kai Trepka, Troy M. Robinson, et al.
Pagina's: 301 - 315
Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) plus ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3(2023)
Volume: 34
Auteurs: J. Mazieres, M. Duruisseaux, H. Curcio, C. Morizane, R. Galot, Sylvie Rottey, J. A. Stratmann, Y. Ma, M. Bouzaggou, L. Geng, et al.
Pagina's: S1076 - S1077
Infrared spectroscopy : a new frontier in hematological disease diagnosis(2023)
Auteurs: Charlotte Delrue, Reinhart Speeckaert, Matthijs Oyaert, Tessa Kerre, Sylvie Rottey, Renaat Coopman, Wouter Huvenne, Sander De Bruyne, Marijn Speeckaert
Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors : the CHEERS phase 2 randomized clinical trial(2023)
Auteurs: Mathieu Spaas, Nora Sundahl, Vibeke Kruse, Sylvie Rottey, Daan De Maeseneer, Fréderic Duprez, Yolande Lievens, Veerle Surmont, Lieve Brochez, Dries Reynders, et al.
Pagina's: 1205 - 1213
GeNeo : agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative(2023)
Volume: 34
Auteurs: P. G. Aftimos, K. Punie, L. Decoster, C. Van Marcke de Lummen, A. Hebrant, G. Raicevic, E. Van Valckenborgh, B. Maes, J. Maetens, J. J. Collignon, et al.
Pagina's: S253 - S254
Incidence, evolution and risk factors of hypophosphatemia in patients with solid tumors receiving ferric carboxymaltose : a retrospective cohort study(2023)
Auteurs: Alexander Decruyenaere, Koen Kortbeek, Sigurd Delanghe, Sylvie Rottey, Hannelore Denys, Lore Lapeire
Pagina's: 298 - 307

Onderzoeker

Sylvie Rottey

Affiliaties

Projecten

Publicaties